Lantern Pharma (LTRN) Stock

$5.30 0.16 (3.11%)
Market Cap: $57.16M | NASDAQ

Lantern Pharma Chart


Company Profile

Price: $5.30

Market Cap: $57.16M

Exchange: NASDAQ

CEO: Mr. Panna Sharma PH.D.

Sector: Healthcare

Industry: Biotechnology

Employees: -0.00B

Headquarters: Dallas, TX

Website: Lantern Pharma

Business Summary

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Lantern Pharma News

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announced that the first patient has been enrolled and dosed in Taiwan for its Phase 2 HARMONIC™ clinical trial evaluating LP-300 in never-smoker patients with non-small cell lung cancer (NSCLC) who have progressed after receiving treatment with tyrosine kinase inhibitors (TKIs). The enrollment of the first patie.

News image

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the FDA has granted Fast Track Designation for investigational drug candidate, LP-184, for treatment of Triple Negative Breast Cancer (TNBC). This marks the second Fast Track Designation received for LP-184 in 2024, following its designation for.

News image

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence company transforming oncology drug development, and its wholly-owned subsidiary Starlight Therapeutics, focused exclusively on CNS and brain cancers, today announced the presentation of new preclinical data and Phase 1b trial design for LP-184 (to be developed as STAR-001 for CNS indications) in glioblastoma at the Society for Neuro-Oncology (SNO) 2024 Annual Meeting in Houston, Texas. The poster presentatio.

News image

Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call Transcript

Lantern Pharma Inc. (NASDAQ:LTRN ) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Panna Sharma - President and CEO David Margrave - Chief Financial Officer Kishor Bhatia - Chief Scientific Officer Operator Good afternoon, and welcome to our Third Quarter 2024 earnings call. As a reminder, this call is being recorded, and all attendees are in a listen-only mode.

News image

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the third quarter 2024, ending September 30, 2024. "Lantern is achieving remarkable momentum, balancing meticulous execution with innovation. While progressing on.

News image

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board

DALLAS--(BUSINESS WIRE)--Starlight Therapeutics, a wholly-owned subsidiary of Lantern Pharmaceuticals (NASDAQ: LTRN), formed to develop transformative CNS cancer treatments with AI-powered innovation, announced today the formation of a Scientific Advisory Board (“SAB”) to support the development of lead compound STAR-001. The inaugural SAB will work closely with Starlight's management team to provide strategic guidance and critical expert insights into the development of STAR-001 in CNS and bra.

News image

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it will host its third quarter 2024 operating and financial results webcast on Thursday, November 7, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Management intends to discuss the operating and financial.

News image

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern management will be presenting at the ThinkEquity Conference on Wednesday, October 30, 2024, at 10:30 a.m. ET at the Mandarin Oriental in New York, NY. Webcast Link: https://www.meetmax.com/sched/event_106721/conference_register.html Confe.

News image

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the FDA has granted Fast Track Designation for investigational drug candidate, LP-184, for treatment of Glioblastoma. LP-184 is currently in a Phase 1A clinical trial designed to evaluate the safety and tolerability of the synthetically lethal in.

News image

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children's Cancers

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, announced today that the company has been granted three rare pediatric disease designations (RPDD) by the FDA. Lantern was granted these rare pediatric disease designations in: malignant rhabdoid tumors (MRT), rhabdomyosarcoma (.

News image

Lantern Pharma Inc. (LTRN) Q2 2024 Earnings Call Transcript

Lantern Pharma Inc. (NASDAQ:LTRN ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Panna Sharma - President and CEO David Margrave - Chief Financial Officer Dr. Reggie Ewesuedo - Vice President, Clinical Development Conference Call Participants John Vandermosten - Zacks Research Operator Good afternoon. And welcome to our Second Quarter 2024 Earnings Call.

News image

Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc., (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced that the Japan Patent Office (JPO) has issued a Certificate of Patent for patent application no. 2021-513267 / registration no. 7489966 directed to Lantern Pharma's drug candidate LP-284 ((+)N-hydroxy-N-(methyla.

News image

The 3 Best Machine Learning Stocks to Quadruple Your Money by 2035

One of the hottest investment trends to jump on at the moment is machine learning stocks to buy. Valued at about $79.3 billion at the moment, it's expected to balloon to $503.4 billion by the time 2030 rolls around, according to Statista.

News image

Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the first quarter 2024, ended March 31, 2024. “Our company made meaningful progress across multiple clinical trials and in furthering our AI platform this past qua.

News image

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism

PARIS & DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a leading artificial intelligence (AI) oncology drug discovery and development company, today announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase (PDI)(1) inhibitor drug candidate XCE853 in novel and targeted cancer indications. Lantern will be leveraging its proprietary RADR® AI platform to uncover bi.

News image

Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it will host its first quarter 2024 financial results webcast on Thursday, May 9, at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Management intends to discuss the operating and financial results for the.

News image

3 Machine Learning Stocks with the Potential to Make You an Overnight Millionaire

Keep an eye on machine learning stocks. Companies are tripping over each other for the technology, which involves feeding data to a machine so it can learn and even make human-like decisions.

News image

Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, announced today that – the company has launched Webinar Wednesdays, a webinar series that focuses on areas of high oncology drug development interest with leading physicians, scientists and Lantern collaborators in drug developm.

News image

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan

Approximately 33% of all non-small cell lung cancer patients in East Asia are never smokers – a growing and unaddressed patient population. Dr. Yashushi Goto a leading lung cancer clinician-scientist at the renowned National Cancer Center of Japan will be a lead investigator. DALLAS–(BUSINESS WIRE)–Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing … The post Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lu...

News image

Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcript

Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcript

News image

Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the fourth quarter and fiscal year ended December 31, 2023. “This past quarter and the entire year of 2023 was a period of meaningful and remarkable progress for o.

News image

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR®, with multiple clinical stage drug programs, today announced the dosing of the first two patients in the Phase 1 clinical trial evaluating Lantern's investigational new drug LP-284 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL), including mantle cell ly.

News image

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it will host its fourth quarter and fiscal year 2023 financial results webcast on Monday, March 18, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Management intends to discuss the operating and financial.

News image

Lantern To Participate in H.C Wainwright & Co.'s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a leader in AI-driven cancer drug discovery and development, announced that it will be presenting at a virtual conference being hosted by HCW. The conference will be on Thursday, March 7th, and is a virtual event. Lantern Pharma's CEO, Mr. Panna Sharma, will be discussing and presenting via a fireside chat format at The 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference at approximately 2 pm E.

News image

Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers

DALLAS--(BUSINESS WIRE)--Press release about Lantern Pharma's ADC program focused on cryptophycin drug-payload ADC being developed in collaboration with Bielefeld.

News image

Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer

DALLAS--(BUSINESS WIRE)--Starlight Therapeutics— a Lantern Pharma (Nasdaq: LTRN) subsidiary focused exclusively on the clinical development of therapies for central nervous system and brain cancers with limited or no effective therapeutic options— today announced that Marc Chamberlain, M.D. has joined Starlight as its Chief Medical Officer. Dr. Chamberlain will oversee Starlight's clinical operations, which currently include planned clinical trials for glioblastoma and other high-grade gliomas,.

News image

The 3 Most Undervalued AI Penny Stocks to Buy in December

It's easy to understand why investors remain curious about AI penny stocks in December and beyond. Leading companies in the artificial intelligence (AI) industry have multiplied in value in 2023.

News image

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)

DALLAS--(BUSINESS WIRE)--FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL). This is the second ODD for LP-284.

News image

Lantern Pharma Inc. (LTRN) Q3 2023 Earnings Call Transcript

Lantern Pharma Inc. (NASDAQ:LTRN ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Panna Sharma - President and Chief Executive Officer David Margrave - Chief Financial Officer Conference Call Participants Operator Good afternoon, and welcome to our Third Quarter 2023 Earnings Call. As a reminder, this call is being recorded and all attendees are in a listen-only mode.

News image

Lantern Pharma Earnings

This section highlights Lantern Pharma's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.

Next Earnings Date

Date: March 17, 2025
Time: Before Market
Est. EPS: $-0.59
Status: Unconfirmed

Last Earnings Results

Date: November 07, 2024
EPS: $-0.42
Est. EPS: $-0.56
Revenue: $-

Earnings Call Transcripts

Transcript Quarter Year Date Estimated EPS Actual EPS
Read Transcript Q3 2024 2024-11-08 N/A N/A
Read Transcript Q1 2024 2024-05-09 $-0.43 $-0.51
Read Transcript Q4 2023 2024-03-18 $-0.40 $-0.39
Read Transcript Q3 2023 2023-11-09 N/A N/A
Read Transcript Q2 2023 2023-08-09 $-0.40 $-0.44
Read Transcript Q1 2023 2023-05-13 N/A N/A

Financial Statements

Access annual & quarterly financial statements for Lantern Pharma, including income statements, balance sheets, and cash flow statements..

Annual Income Statement

Breakdown December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020 December 31, 2019
Revenue $- $- $- $- $-
Cost of Revenue $174.84K $154.68K $97.42K $3.39K $1.63K
Gross Profit $-174.84K $-154.68K $-97.42K $-3.39K $-1.63K
Gross Profit Ratio 0.00% 0.00% 0.00% 0.00% 0.00%
Research and Development Expenses $11.89M $8.60M $7.57M $2.24M $953.18K
General and Administrative Expenses $5.98M $5.83M $5.02M $3.66M $1.48M
Selling and Marketing Expenses $- $- $- $- $-
Selling General and Administrative Expenses $5.98M $5.83M $5.02M $3.66M $1.48M
Other Expenses $- $-31.55K $160.55K $- $-
Operating Expenses $17.88M $14.43M $12.59M $5.91M $2.43M
Cost and Expenses $17.88M $14.43M $12.59M $5.91M $2.43M
Interest Income $765.39K $204.35K $67.93K $- $-
Interest Expense $- $204.35K $- $- $-
Depreciation and Amortization $174.84K $154.68K $97.42K $3.39K $1.63K
EBITDA $-15.79M $-14.42M $-12.27M $-5.90M $-2.43M
EBITDA Ratio 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Income $-17.88M $-14.43M $-12.59M $-5.91M $-2.43M
Operating Income Ratio 0.00% 0.00% 0.00% 0.00% 0.00%
Total Other Income Expenses Net $1.92M $172.81K $228.48K $- $-
Income Before Tax $-15.96M $-14.26M $-12.36M $-5.91M $-2.43M
Income Before Tax Ratio 0.00% 0.00% 0.00% 0.00% 0.00%
Income Tax Expense $- $-172.81K $-67.93K $-202.91K $--0.00B
Net Income $-15.96M $-14.09M $-12.30M $-5.91M $-2.43M
Net Income Ratio 0.00% 0.00% 0.00% 0.00% 0.00%
EPS $-1.47 $-1.30 $-1.13 $-0.95 $-0.39
EPS Diluted $-1.47 $-1.30 $-1.13 $-0.95 $-0.39
Weighted Average Shares Outstanding 10.84M 10.85M 10.90M 6.22M 6.27M
Weighted Average Shares Outstanding Diluted 10.84M 10.85M 10.90M 6.22M 6.27M
SEC Filing Source Source Source Source Source


Income Statement Charts

Breakdown September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020 December 31, 2019
Revenue $- $- $- $261.05K $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Cost of Revenue $- $46.27K $4.06K $44.32K $43.33K $43.76K $43.44K $- $39.10K $38.53K $38.14K $71.10K $- $25.68K $1.34K $- $- $- $- $-
Gross Profit $- $-46.27K $-4.06K $216.74K $-43.33K $-43.76K $-43.44K $- $-39.10K $-38.53K $-38.14K $-71.10K $- $-25.68K $-1.34K $- $- $- $- $-
Gross Profit Ratio 0.00% 0.00% 0.00% 83.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Research and Development Expenses $3.72M $3.89M $4.25M $3.57M $2.21M $3.56M $2.55M $2.25M $702.30K $2.99M $2.66M $2.16M $2.96M $1.16M $1.28M $1.35M $600.77K $157.02K $137.10K $177.47K
General and Administrative Expenses $1.46M $1.52M $1.48M $1.30M $1.31M $1.63M $1.73M $1.57M $1.44M $1.41M $1.41M $1.35M $1.18M $1.31M $1.17M $1.55M $1.10M $676.40K $340.17K $497.70K
Selling and Marketing Expenses $- $-46.27K $-4.06K $-44.32K $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Selling General and Administrative Expenses $1.46M $1.47M $1.48M $1.26M $1.31M $1.63M $1.73M $1.57M $1.44M $1.41M $1.41M $1.35M $1.18M $1.31M $1.17M $1.55M $1.10M $676.40K $340.17K $497.70K
Other Expenses $- $260.30K $90.24K $424.07K $115.78K $326.08K $284.72K $- $-171.65K $-152.59K $-77.80K $28.15K $17.68K $114.72K $- $- $- $- $- $-
Operating Expenses $5.18M $5.36M $5.73M $4.83M $3.52M $5.19M $4.29M $3.83M $2.15M $4.39M $4.07M $3.51M $4.15M $2.48M $2.45M $2.90M $1.70M $833.42K $477.28K $675.17K
Cost and Expenses $5.18M $5.41M $5.73M $4.88M $3.52M $5.19M $4.29M $3.83M $2.15M $4.39M $4.07M $3.51M $4.15M $2.48M $2.45M $2.90M $1.70M $833.42K $477.28K $675.17K
Interest Income $191.35K $188.66K $200.95K $267.39K $246.39K $117.82K $133.78K $74.68K $52.22K $55.03K $22.42K $- $77.22K $47.89K $- $- $- $- $- $-
Interest Expense $- $- $- $418.50K $- $- $- $- $52.22K $55.03K $22.42K $29.03K $- $- $- $- $- $- $- $-
Depreciation and Amortization $4.39K $46.27K $4.06K $44.32K $43.33K $43.76K $43.44K $2.76K $39.10K $38.53K $38.14K $71.10K $1.85K $25.68K $1.34K $1.09K $1.09K $-0.00B $-0.00B $-0.00B
EBITDA $-5.18M $-5.41M $-5.73M $-4.87M $-3.52M $-5.19M $-4.28M $-3.82M $-2.14M $-4.39M $-4.06M $-3.47M $-4.15M $-2.48M $-2.45M $-2.89M $-1.70M $-832.76K $-476.74K $-674.63K
EBITDA Ratio 0.00% 0.00% 0.00% -1851.38% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Income $-5.18M $-5.41M $-5.73M $-4.88M $-3.52M $-5.19M $-4.29M $-3.83M $-2.15M $-4.39M $-4.07M $-3.51M $-4.15M $-2.48M $-2.45M $-2.90M $-1.70M $-833.42K $-477.28K $-675.17K
Operating Income Ratio 0.00% 0.00% 0.00% -1868.36% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Total Other Income Expenses Net $673.88K $448.95K $291.19K $691.46K $362.17K $443.90K $418.50K $445.17K $-119.42K $-97.56K $-55.38K $-29.03K $94.90K $162.61K $- $- $- $- $- $-
Income Before Tax $-4.51M $-4.96M $-5.44M $-4.19M $-3.16M $-4.75M $-3.87M $-3.38M $-2.26M $-4.49M $-4.12M $-3.54M $-4.05M $-2.32M $-2.45M $-2.90M $-1.70M $-833.42K $-477.28K $-675.17K
Income Before Tax Ratio 0.00% 0.00% 0.00% -1603.48% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Income Tax Expense $- $-0.00B $--0.00B $-0.00B $-246.39K $-117.82K $-418.50K $- $119.42K $97.56K $55.38K $29.03K $-77.22K $-47.89K $-0.00B $-5.91B $- $- $- $-
Net Income $-4.51M $-4.96M $-5.44M $-4.19M $-3.16M $-4.75M $-3.45M $-3.38M $-2.38M $-4.59M $-4.18M $-3.54M $-4.05M $-2.32M $-2.45M $-2.90M $-1.70M $-833.42K $-477.28K $-675.17K
Net Income Ratio 0.00% 0.00% 0.00% -1603.48% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS $-0.42 $-0.46 $-0.51 $-0.39 $-0.29 $-0.44 $-0.32 $0.00 $-0.22 $-0.42 $-0.38 $-0.32 $-0.36 $-0.21 $-0.24 $-0.47 $-0.27 $-0.31 $-0.08 $-0.11
EPS Diluted $-0.42 $-0.46 $-0.51 $-0.39 $-0.29 $-0.44 $-0.32 $0.00 $-0.22 $-0.42 $-0.38 $-0.32 $-0.36 $-0.21 $-0.24 $-0.47 $-0.27 $-0.31 $-0.08 $-0.11
Weighted Average Shares Outstanding 10.76M 10.76M 10.74M 10.80M 10.86M 10.86M 10.86M - 10.84M 10.83M 10.88M 11.17M 11.19M 11.18M 10.07M 6.22M 6.22M 2.72M 6.03M 6.22M
Weighted Average Shares Outstanding Diluted 10.76M 10.76M 10.74M 10.80M 10.86M 10.86M 10.86M - 10.84M 10.83M 10.88M 11.19M 11.19M 11.18M 10.07M 6.22M 6.22M 2.72M 6.03M 6.22M
SEC Filing Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source

Annual Balance Sheet

Breakdown December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020 December 31, 2019
Cash and Cash Equivalents $21.94M $37.20M $51.52M $19.23M $1.23M
Short Term Investments $19.36M $17.99M $19.20M $- $-
Cash and Short Term Investments $41.30M $55.20M $70.73M $19.23M $1.23M
Net Receivables $- $- $- $- $-
Inventory $- $-592.00K $-181.00K $- $-
Other Current Assets $1.61M $3.53M $1.03M $806.00K $-0.00B
Total Current Assets $43.34M $58.72M $72.72M $20.24M $1.23M
Property Plant Equipment Net $280.42K $95.69K $216.19K $21.51K $8.76K
Goodwill $- $- $- $- $-
Intangible Assets $- $- $- $- $-
Goodwill and Intangible Assets $- $- $- $- $-
Long Term Investments $- $- $1.00M $- $-
Tax Assets $- $- $- $- $-
Other Non-Current Assets $25.87K $17.89K $17.89K $101.20K $191.00K
Total Non-Current Assets $306.29K $113.58K $1.23M $122.71K $199.76K
Other Assets $- $- $- $- $-
Total Assets $43.65M $58.84M $73.95M $20.36M $1.43M
Account Payables $- $932.41K $681.11K $432.34K $478.29K
Short Term Debt $172.97K $52.89K $152.06K $- $-
Tax Payables $- $- $- $- $-
Deferred Revenue $- $-2.75M $-2.17M $- $-
Other Current Liabilities $2.51M $1.81M $1.49M $120.00K $11.00K
Total Current Liabilities $2.68M $2.80M $2.33M $552.34K $489.29K
Long Term Debt $61.50K $- $52.89K $108.50K $-
Deferred Revenue Non-Current $- $- $- $- $-
Deferred Tax Liabilities Non-Current $- $- $- $- $-
Other Non-Current Liabilities $- $- $- $- $-
Total Non-Current Liabilities $61.50K $52.89K $52.89K $108.50K $-
Other Liabilities $- $-52.89K $- $- $-
Total Liabilities $2.74M $2.80M $2.38M $660.84K $489.29K
Preferred Stock $- $- $- $- $14.02K
Common Stock $1.07K $1.09K $1.11K $-0.00B $11.37K
Retained Earnings $-55.24M $-39.28M $-25.02M $-12.66M $-6.75M
Accumulated Other Comprehensive Income Loss $-107.46K $-371.39K $-92.69K $--0.00B $-
Other Total Stockholders Equity $96.26M $95.69M $96.69M $32.36M $7.69M
Total Stockholders Equity $40.91M $56.04M $71.57M $19.70M $943.28K
Total Equity $40.91M $56.04M $71.57M $19.70M $943.28K
Total Liabilities and Stockholders Equity $43.65M $58.84M $73.95M $20.36M $1.43M
Minority Interest $- $- $- $- $-
Total Liabilities and Total Equity $43.65M $58.84M $73.95M $20.36M $1.43M
Total Investments $19.36M $17.99M $19.20M $- $-
Total Debt $234.47K $52.89K $204.95K $108.50K $-
Net Debt $-21.70M $-37.15M $-51.32M $-19.12M $-1.23M


Balance Sheet Charts

Breakdown September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020 December 31, 2019
Cash and Cash Equivalents $8.10M $12.98M $18.36M $21.94M $25.57M $28.42M $32.48M $37.20M $39.26M $43.36M $46.65M $51.52M $54.67M $61.35M $81.37M $19.23M $20.80M $23.80M $634.25K $1.23M
Short Term Investments $19.95M $20.29M $20.00M $19.36M $19.35M $19.53M $19.06M $17.99M $18.57M $18.79M $18.56M $19.20M $19.16M $18.23M $- $- $- $- $- $-
Cash and Short Term Investments $28.05M $33.26M $38.36M $41.30M $44.93M $47.95M $51.54M $55.20M $57.83M $62.15M $65.22M $70.73M $73.83M $79.59M $81.37M $19.23M $20.80M $23.80M $634.25K $1.23M
Net Receivables $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Inventory $- $- $- $- $- $- $- $- $-305.00K $-339.00K $-228.00K $-181.00K $- $- $- $- $- $- $- $-
Other Current Assets $1.87M $2.03M $1.11M $2.04M $2.50M $4.95M $3.63M $3.53M $4.19M $1.33M $293.00K $1.03M $1.46M $1.86M $360.00K $806.00K $2.98M $1.80M $132.15K $-0.00B
Total Current Assets $29.92M $35.29M $39.47M $43.34M $47.43M $51.04M $55.17M $58.72M $62.02M $65.66M $67.66M $72.72M $76.34M $82.13M $82.48M $20.24M $22.48M $25.60M $766.39K $1.23M
Property Plant Equipment Net $335.57K $263.34K $237.49K $280.42K $319.66K $358.20K $308.79K $95.69K $126.73K $157.75K $180.29K $216.19K $251.67K $283.10K $20.16K $21.51K $17.61K $15.38K $8.22K $8.76K
Goodwill $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Intangible Assets $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Goodwill and Intangible Assets $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Long Term Investments $- $- $- $- $- $- $- $- $- $541.18K $541.18K $1.00M $1.00M $- $- $- $- $- $- $-
Tax Assets $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Other Non-Current Assets $36.74K $32.02K $25.87K $25.87K $25.87K $25.87K $32.97K $17.89K $17.89K $17.89K $17.89K $17.89K $17.89K $17.89K $- $101.20K $- $- $263.38K $191.00K
Total Non-Current Assets $372.30K $295.35K $263.36K $306.29K $345.53K $384.07K $341.75K $113.58K $144.62K $716.82K $739.36K $1.23M $1.27M $300.99K $20.16K $122.71K $17.61K $15.38K $271.60K $199.76K
Other Assets $- $- $-0.00B $- $- $- $- $- $-0.00B $- $- $- $- $- $- $- $- $- $- $-
Total Assets $30.29M $35.59M $39.73M $43.65M $47.77M $51.43M $55.51M $58.84M $62.16M $66.38M $68.40M $73.95M $77.61M $82.43M $82.50M $20.36M $22.49M $25.61M $1.04M $1.43M
Account Payables $- $4.44M $1.61M $942.21K $2.09M $2.85M $1.19M $- $985.97K $2.02M $690.65K $681.11K $722.64K $1.09M $664.53K $432.34K $805.56K $467.99K $439.26K $478.29K
Short Term Debt $197.29K $328.00K $178.02K $172.97K $336.03K $326.29K $119.58K $52.89K $92.02K $130.71K $155.19K $152.06K $148.96K $145.90K $- $- $- $102.83K $53.27K $-
Tax Payables $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Deferred Revenue $- $-4.44M $-3.78M $-1.74K $-2.09M $-2.85M $-2.67M $- $-3.05M $-5.17B $-2.92M $-2.33B $-1.64M $- $- $- $- $- $-439.26K $-
Other Current Liabilities $3.40M $-164.00K $2.16M $1.56M $-168.01K $-163.15K $1.49M $2.75M $2.06M $3.16M $2.23M $1.49M $914.00K $1.45M $- $120.00K $9.00K $1.71M $9.00K $11.00K
Total Current Liabilities $3.60M $4.60M $3.95M $2.68M $2.25M $3.02M $2.79M $2.80M $3.14M $5.30M $3.07M $2.33M $1.79M $2.69M $664.53K $552.34K $814.56K $2.28M $501.53K $489.29K
Long Term Debt $93.95K $54.69K $15.56K $61.50K $106.52K $150.71K $140.63K $- $- $- $13.30K $52.89K $92.02K $130.71K $108.50K $108.50K $108.50K $108.50K $- $-
Deferred Revenue Non-Current $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Deferred Tax Liabilities Non-Current $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Other Non-Current Liabilities $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Non-Current Liabilities $93.95K $54.69K $15.56K $61.49K $106.52K $150.71K $140.63K $- $92.02K $5.30M $13.30K $52.89K $92.02K $130.71K $108.50K $108.50K $108.50K $108.50K $- $-
Other Liabilities $- $-0.00B $-0.00B $-0.00B $- $- $- $- $-92.02K $-5.30M $- $- $- $- $- $- $- $- $- $-
Total Liabilities $3.70M $4.66M $3.97M $2.74M $2.36M $3.17M $2.93M $2.80M $3.14M $5.30M $3.09M $2.38M $1.88M $2.82M $773.03K $660.84K $923.06K $2.39M $501.53K $489.29K
Preferred Stock $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-0.00B $-0.00B $14.02K
Common Stock $1.08K $1.08K $1.08K $1.07K $1.09K $1.09K $1.09K $1.09K $1.09K $1.08K $1.08K $1.11K $1.12K $1.12K $1.12K $-0.00B $-0.00B $-0.00B $-0.00B $11.37K
Retained Earnings $-70.15M $-65.64M $-60.69M $-55.24M $-51.06M $-47.90M $-43.15M $-39.28M $-35.90M $-33.64M $-29.14M $-25.02M $-21.48M $-17.43M $-15.11M $-12.66M $-9.76M $-8.06M $-7.23M $-6.75M
Accumulated Other Comprehensive Income Loss $-25.26K $-6.58K $1.86K $-107.46K $-138.79K $-261.84K $-299.68K $-371.39K $-435.04K $-348.48K $-311.47K $-92.69K $-102.69K $-47.56K $-0.00B $--0.00B $--0.00B $--0.00B $- $-
Other Total Stockholders Equity $96.77M $96.58M $96.45M $96.26M $96.61M $96.42M $96.02M $95.69M $95.36M $95.06M $94.77M $96.69M $97.31M $97.09M $96.84M $32.36M $31.33M $31.29M $7.77M $7.69M
Total Stockholders Equity $26.60M $30.93M $35.77M $40.91M $45.41M $48.26M $52.58M $56.04M $59.03M $61.08M $65.32M $71.57M $75.73M $79.61M $81.73M $19.70M $21.57M $23.23M $536.47K $943.28K
Total Equity $26.60M $30.93M $35.77M $40.91M $45.41M $48.26M $52.58M $56.04M $59.03M $61.08M $65.32M $71.57M $75.73M $79.61M $81.73M $19.70M $21.57M $23.23M $536.47K $943.28K
Total Liabilities and Stockholders Equity $30.29M $35.59M $39.73M $43.65M $47.77M $51.43M $55.51M $58.84M $62.16M $66.38M $68.40M $73.95M $77.61M $82.43M $82.50M $20.36M $22.49M $25.61M $1.04M $1.43M
Minority Interest $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Liabilities and Total Equity $30.29M $35.59M $39.73M $43.65M $47.77M $51.43M $55.51M $58.84M $62.16M $66.38M $68.40M $73.95M $77.61M $82.43M $82.50M $20.36M $22.49M $25.61M $1.04M $1.43M
Total Investments $19.95M $20.29M $20.00M $19.36M $19.35M $19.53M $19.06M $17.99M $18.57M $18.79M $18.56M $19.20M $19.16M $18.23M $- $- $- $- $- $-
Total Debt $291.24K $218.70K $193.58K $234.47K $274.53K $313.86K $260.22K $52.89K $92.02K $130.71K $168.49K $204.95K $240.98K $276.60K $108.50K $108.50K $108.50K $211.33K $53.27K $-
Net Debt $-7.81M $-12.76M $-18.16M $-21.70M $-25.30M $-28.11M $-32.22M $-37.15M $-39.17M $-43.23M $-46.48M $-51.32M $-54.43M $-61.08M $-81.27M $-19.12M $-20.69M $-23.59M $-580.98K $-1.23M

Annual Cash Flow

Breakdown December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020 December 31, 2019
Net Income $-15.96M $-14.26M $-12.36M $-5.91M $-2.43M
Depreciation and Amortization $14.62K $10.08K $6.76K $3.39K $1.63K
Deferred Income Tax $- $- $112.56K $-1.08M $251.65K
Stock Based Compensation $1.07M $1.19M $961.54K $1.19M $117.76K
Change in Working Capital $538.02K $-611.86K $599.96K $-939.06K $180.88K
Accounts Receivables $- $-158.40K $-71.66K $- $-
Inventory $- $- $- $- $-
Accounts Payables $- $580.36K $1.62M $117.17K $372.66K
Other Working Capital $538.02K $-1.03M $-950.47K $-1.06M $-191.79K
Other Non Cash Items $-5.17K $906.49K $90.66K $1.08M $-251.65K
Net Cash Provided by Operating Activities $-14.35M $-12.77M $-10.59M $-5.65M $-2.13M
Investments in Property Plant and Equipment $-18.73K $-27.84K $-15.50K $-16.14K $-5.72K
Acquisitions Net $- $-179.27M $19.53B $- $-
Purchases of Investments $-8.20M $-3.91M $-19.58M $- $-
Sales Maturities of Investments $7.28M $4.12M $64.09K $- $-
Other Investing Activities $--0.00B $179.27M $-19.53B $-5.72M $-
Net Cash Used for Investing Activities $-930.21K $179.27K $-19.53M $-16.14K $-5.72K
Debt Repayment $- $- $- $108.50K $-
Common Stock Issued $- $- $69.00M $26.25M $2.92M
Common Stock Repurchased $-500.00K $-2.48M $-939.67K $- $-
Dividends Paid $- $- $- $- $-
Other Financing Activities $- $-2.48M $-5.58M $26.25M $2.92M
Net Cash Used Provided by Financing Activities $-500.00K $-2.18K $63.42M $23.66M $2.92M
Effect of Forex Changes on Cash $-28.46K $-10.61K $1.07K $- $-
Net Change in Cash $-15.81M $-14.78M $33.30M $18.00M $786.87K
Cash at End of Period $21.94M $37.74M $52.52M $19.23M $1.23M
Cash at Beginning of Period $37.74M $52.52M $19.23M $1.23M $445.16K
Operating Cash Flow $-14.35M $-12.77M $-10.59M $-5.65M $-2.13M
Capital Expenditure $-18.73K $-27.84K $-15.50K $-16.14K $-5.72K
Free Cash Flow $-14.37M $-12.80M $-10.61M $-5.67M $-2.13M

Cash Flow Charts

Breakdown September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020 December 31, 2019
Net Income $-4.51M $-4.96M $-5.44M $-4.19M $-3.16M $-4.75M $-3.87M $-3.38M $-2.26M $-4.49M $-4.12M $-3.54M $-4.05M $-2.32M $-2.45M $-2.90M $-1.70M $-833.42K $-477.28K $-675.17K
Depreciation and Amortization $4.39K $46.27K $4.06K $44.32K $3.71K $3.51K $3.42K $2.76K $2.95K $2.38K $1.99K $1.99K $1.85K $1.58K $1.34K $1.09K $1.09K $-0.00B $-0.00B $-0.00B
Deferred Income Tax $- $- $- $180.44K $95.50K $38.93K $- $- $- $312.05K $225.24K $206.88K $14.91K $- $- $- $- $- $- $-
Stock Based Compensation $179.17K $134.17K $134.06K $150.84K $190.75K $392.39K $333.53K $330.10K $301.11K $289.53K $267.00K $245.93K $224.41K $245.68K $245.52K $1.02M $43.51K $105.36K $18.46K $63.40K
Change in Working Capital $-914.35K $-301.64K $2.13M $879.22K $-780.24K $679.39K $-240.35K $380.34K $-2.38M $1.12M $263.66K $977.34K $-867.23K $428.85K $60.99K $301.95K $-1.23M $236.52K $-244.77K $-97.65K
Accounts Receivables $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Inventory $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Accounts Payables $-1.03M $661.18K $1.27M $419.92K $-767.87K $179.07K $-67.30K $- $-2.14M $2.28M $742.52K $1.49M $-543.46K $513.54K $164.07K $- $- $- $- $-
Other Working Capital $118.98K $-962.83K $860.13K $459.31K $-12.37K $500.32K $67.30K $380.34K $-237.81K $-1.16M $-478.86K $-438.94K $-323.77K $-84.69K $-103.08K $-0.00B $-1.60K $-0.00B $-244.77K $--0.00B
Other Non Cash Items $-345.76K $-544.40K $-1.03M $-454.25K $39.61K $40.25K $14.01K $--0.00B $297.86K $36.15K $36.15K $275.99K $12.36K $-85.12K $84.13K $--0.00B $-0.00B $-0.00B $--0.00B $-0.00B
Net Cash Provided by Operating Activities $-5.58M $-5.19M $-3.07M $-3.39M $-3.61M $-3.59M $-3.76M $-2.67M $-4.04M $-2.73M $-3.33M $-2.04M $-4.68M $-1.73M $-2.14M $-1.57M $-2.89M $-490.87K $-703.05K $-708.88K
Investments in Property Plant and Equipment $-3.03K $-4.27K $-2.22K $-5.08K $-4.78K $- $-8.88K $-6.96K $-6.71K $-14.18K $- $--0.00B $-3.48K $-12.01K $- $-4.99K $-3.32K $--0.00B $- $-
Acquisitions Net $- $- $- $--0.00B $--0.00B $- $-2.15M $- $-0.00B $2.02M $- $- $- $- $- $- $- $- $- $-
Purchases of Investments $-3.12M $-8.35M $-6.01M $-1.56M $-731.49K $-2.81M $-3.10M $-590.18K $-1.32M $-2.00M $- $-298.05K $-999.02K $-18.28M $- $- $- $- $- $-
Sales Maturities of Investments $-13.61M $8.15M $5.46M $1.82M $968.00K $2.35M $2.15M $1.20M $1.25M $1.49M $176.52K $64.09K $- $- $- $- $- $- $- $-
Other Investing Activities $17.41M $--0.00B $--0.00B $-0.00B $-0.00B $--0.00B $2.15M $- $--0.00B $-2.02M $-0.00B $64.09K $-3.48K $-18.28K $- $-16.13M $- $- $- $-
Net Cash Used for Investing Activities $680.35K $-202.06K $-556.17K $256.18K $231.73K $-457.24K $-960.88K $602.86K $-74.36K $-525.75K $176.52K $-233.96K $-1.00M $-18.29M $- $-4.99K $-3.32K $--0.00B $- $-
Debt Repayment $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-102.83K $158.07K $53.27K $-
Common Stock Issued $-54.72K $- $54.72K $- $- $- $- $- $- $- $- $66.86K $- $--0.00B $69.00M $- $52.00K $- $- $-
Common Stock Repurchased $- $- $- $-500.00K $- $- $- $- $- $- $-2.48M $-939.67K $- $--0.00B $- $- $- $- $- $-
Dividends Paid $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Other Financing Activities $11.99K $- $54.72K $- $- $- $- $-2.48M $- $- $299.79K $-872.81K $- $- $-4.71M $--0.00B $- $23.50M $52.00K $-
Net Cash Used Provided by Financing Activities $11.99K $- $54.72K $-500.00K $- $-690.80K $- $- $- $- $-2.18K $-872.81K $- $--0.00B $64.29M $--0.00B $-102.83K $23.66M $105.27K $-
Effect of Forex Changes on Cash $16.17K $11.32K $-9.83K $-4.81K $-12.24K $-6.43K $-4.98K $9.90K $7.65K $-30.43K $2.28K $-0.00B $- $- $- $- $- $- $- $-
Net Change in Cash $-4.87M $-5.38M $-3.58M $-3.63M $-3.39M $-4.06M $-4.72M $-2.06M $-4.10M $-3.29M $-5.33M $-3.14M $-5.69M $-20.02M $62.14M $-1.57M $-3.00M $23.16M $-597.78K $-708.88K
Cash at End of Period $8.10M $12.98M $18.36M $21.94M $25.57M $28.96M $33.02M $37.74M $39.80M $43.90M $47.19M $52.52M $55.67M $61.35M $81.37M $19.23M $20.80M $23.80M $634.25K $1.23M
Cash at Beginning of Period $12.98M $18.36M $21.94M $25.57M $28.96M $33.02M $37.74M $39.80M $43.90M $47.19M $52.52M $55.67M $61.35M $81.37M $19.23M $20.80M $23.80M $634.25K $1.23M $1.94M
Operating Cash Flow $-5.58M $-5.19M $-3.07M $-3.39M $-3.61M $-3.59M $-3.76M $-2.67M $-4.04M $-2.73M $-3.33M $-2.04M $-4.68M $-1.73M $-2.14M $-1.57M $-2.89M $-490.87K $-703.05K $-708.88K
Capital Expenditure $-3.03K $-4.27K $-2.22K $-5.08K $-4.78K $- $-8.88K $-6.96K $-6.71K $-14.18K $- $--0.00B $-3.48K $-12.01K $- $-4.99K $-3.32K $--0.00B $- $-
Free Cash Flow $-5.59M $-5.19M $-3.07M $-3.39M $-3.62M $-3.59M $-3.77M $-2.68M $-4.04M $-2.75M $-3.33M $-2.04M $-4.69M $-1.74M $-2.14M $-1.57M $-2.89M $-490.88K $-703.05K $-708.88K


Lantern Pharma Stock Forecast

Analyst ratings, price targets, and earnings estimates for LTRN.

LTRN Analyst Ratings

Strong Buy

Buy
1
Hold
0
Sell
0

Based on 1 analysts in the past 3 months

Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
High $-
Average $-
Low $-
0 analysts
Net Income Estimates
High $-18.81M
Average $-18.81M
Low $-18.81M
0 analysts
EPS Estimates
High $-1.74
Average $-1.74
Low $-1.74
1 analysts
Revenue Estimates
High $1.95M
Average $1.95M
Low $1.95M
1 analysts
Net Income Estimates
High $-12.36M
Average $-12.36M
Low $-12.36M
1 analysts
EPS Estimates
High $-1.14
Average $-1.14
Low $-1.14
1 analysts
Revenue Estimates
High $14.60M
Average $14.60M
Low $14.60M
1 analysts
Net Income Estimates
High $-13.88M
Average $-13.88M
Low $-13.88M
1 analysts
EPS Estimates
High $-1.28
Average $-1.28
Low $-1.28
1 analysts
Revenue Estimates
High $33.80M
Average $33.80M
Low $33.80M
1 analysts
Net Income Estimates
High $-9.11M
Average $-9.11M
Low $-9.11M
1 analysts
EPS Estimates
High $-0.84
Average $-0.84
Low $-0.84
1 analysts
Latest Price Target Updates
Date Analyst Firm Price Target Price When Posted Upside

Lantern Pharma Dividends

Explore Lantern Pharma's dividend history, including dividend yield, payout ratio, and historical payments.

Lantern Pharma does not currently pay a dividend.

Peers: Biotechnology

This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.

Company Market Cap Price EPS P/E Ratio P/B Ratio
TFFP Logo
TFF Pharmaceuticals, Inc.
TFFP
$288.80K $0.07 $-11.85 $-0.59 $1.32
GBIO Logo
Generation Bio Co.
GBIO
$54.77M $0.82 $-1.96 $-0.84 $0.52
LYRA Logo
Lyra Therapeutics, Inc.
LYRA
$12.49M $0.19 $-1.26 $-4.16 $2.92
IMNM Logo
Immunome, Inc.
IMNM
$956.83M $11.30 $-5.38 $-1.99 $1.77
CUE Logo
Cue Biopharma, Inc.
CUE
$83.62M $1.32 $-1.11 $-2.38 $3.26
Current Reports (8-K)
Ownership